Axonics, Inc.

Health Care
Medical/Dental Instruments
www.axonics.com

Moat Score
Safety Score

Market Cap $3.62B
PE -640
Debt $0.00
Cash $261.53M
EV $3.36B
FCF $5.37M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$5.66M
EBIT	-$3.01M
ROE	-1%
ROA	-0%
FCF	$5.37M
Equity	$664.49M
Growth Stability	1
PE	-639.71
PB	5.45
P/FCF	673.88
P/S	8.38
Price/Cash	0.07
Debt/Equity	0
Debt/FCF	0
Net Margins	-4%
Gross Margins	77%
Op. Margins	-1%
Sales Growth YoY	25%
Sales Growth QoQ	1%
Sales CAGR	185%
FCF CAGR	1%
Equity CAGR	38%
Earnings Growth YoY	-101%
Earnings Growth QoQ	-100%

Sales CAGR 5Y	74%
FCF CAGR 5Y	3%
Equity CAGR 5Y	29%
Earnings CAGR 3Y	38%
Sales CAGR 3Y	38%
FCF CAGR 3Y	17%
Equity CAGR 3Y	15%
Market Cap	$3.62B
Revenue	$431.90M
Assets	$774.17M
Total Debt	$0.00
Cash	$261.53M
Shares Outstanding	51.01M
EV	3.36B
Moat Score	13%
Safety Score	98%
Working Capital	461.5M
Current Ratio	8.16
Gross Profit	$330.81M
Shares Growth 3y	6%
Equity Growth QoQ	3%
Equity Growth YoY	9%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Axonics Inc is a United stated based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinence.

SEC Filings

Direct access to Axonics, Inc. (AXNX) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Axonics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Axonics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Axonics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Axonics, Inc..

Years

Calculation mode

= $56M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$5.4M	$5.4M	$5.4M	$5.5M	$5.5M	$5.6M	$5.6M	$5.6M	$5.7M	$5.7M	$5.8M	$58M
DCF		$4.9M	$4.5M	$4.1M	$3.8M	$3.5M	$3.2M	$2.9M	$2.6M	$2.4M	$2.2M	$22M
Value	$56M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-14K%	-5K%	-578%	-49%	-44%	-22%	-2%	-4%
ROA	-	-19%	-36%	-16%	-13%	-9%	-1%	-0%
ROE	-	-23%	-44%	-19%	-17%	-10%	-1%	-1%

Bad Net Margins (-3.8%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.66	-0.25	-0.49	-0	-	-	0
Debt over Equity	-0	0.15	0.12	0.15	0	-	-	0
Growth Stability	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (0)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	452%	2K%	707%	62%	52%	34%	74%
Earnings YoY growth	-	80%	146%	-31%	46%	-25%	-90%	-
Equity YoY growth	-	-316%	28%	57%	68%	18%	12%	29%
FCF YoY growth	-	70%	160%	2%	-43%	-102%	-675%	3%